| Jul 10 |
AbbVie names new R&D head; Arcutis eczema cream approved
|
| Jul 9 |
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
|
| Jul 9 |
Zevra announces FDA meeting to review its Niemann-Pick disease type C treatment drug
|
| Jul 9 |
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
|
| Jun 25 |
Zevra Therapeutics Expands Executive Leadership Team
|
| Jun 19 |
Breakeven On The Horizon For Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
|
| Jun 18 |
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
|
| Jun 4 |
Zevra Therapeutics files for $350M mixed shelf
|
| Jun 3 |
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
|
| May 30 |
Retail investors account for 59% of Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) ownership, while institutions account for 28%
|
